Please login to the form below

Not currently logged in
Email:
Password:

bladder cancer

This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.

Merck receives FDA approval for Keytruda combination in gastric cancer

Merck receives FDA approval for Keytruda combination in gastric cancer

An estimated 26, 500 people in the US will be diagnosed with gastric cancer in 2023. ... Beyond gastric cancer, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s lymphoma.

Latest news

More from news
Approximately 34 fully matching, plus 135 partially matching documents found.

Latest Intelligence

  • Improving outcomes for prostate cancer patients Improving outcomes for prostate cancer patients

    a later stage, where it is more likely that the cancer is less treatable. ... Unlike the female equivalent – breast cancer – there is no automatic screening for prostate cancer.

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    those living with urothelial carcinoma (UC), the most common type of bladder cancer. ... and metastatic bladder cancer harbouring an FGFR alteration, addressing the considerable unmet need for patients living with this disease.

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... a terminal disease, and more towards helping cancer patients manage their condition effectively.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...